Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study to Evaluate if AC-084 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects

6. juli 2018 oppdatert av: Idorsia Pharmaceuticals Ltd.

A Three-part Single-center, Phase 1 Study to Assess the Tolerability, Safety, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of Ascending Single and Multiple Doses of AC-084 in Healthy Subjects and to Investigate the Pharmacokinetics of a Single Dose of AC-084 in Healthy CYP2C9 Poor Metabolizers

The primary purpose of this first-in-man study is to investigate whether AC-084 is safe and well-tolerated when orally administered at single- and multiple-ascending dose to healthy adults

Studieoversikt

Status

Avsluttet

Forhold

Detaljert beskrivelse

The study is designed in three parts, A, B and C

Part A: single-center, double-blind, randomized, placebo-controlled, single ascending dose

Part B: single-center, double-blind, randomized, placebo-controlled, multiple ascending dose

Part C: single-center, open-label, single dose in CYP2C9 poor metabolizers

Studietype

Intervensjonell

Registrering (Faktiske)

56

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Leeds, Storbritannia, LS2 9LH
        • Covance Clinical Research Unit

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 55 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Signed informed consent in the local language prior to any study-mandated procedure
  • Healthy male subjects for Part A, healthy male and female subjects for Part B and Part C aged between 18 and 55 years (inclusive) at screening
  • No clinically significant findings on physical examination at screening
  • Body mass index (BMI) of 18.0 to 28.0 kg/m2 (inclusive) at screening
  • CYP2C9 poor metabolizers (Part C)

Exclusion Criteria:

  • History or clinical evidence of any disease and/or existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism or excretion of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed)
  • Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions
  • Treatment or substances known to induce CYP enzyme drug metabolism within 30 days prior to first study treatment administration
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol
  • Known allergic reactions or hypersensitivity to the study treatment or drugs of the same class, or any of their excipients
  • For Part A and Part B, CYP2C9 poor metabolizers enrolled in a cohort to be dosed with single or multiple dose of 500 mg or higher of ACT-774312 (confirmed by genotyping before enrollment)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: AC-084, single ascending dose (Part A)
AC-084 administered at different single dose levels in a sequential manner, and in a maximum of 7 dose levels starting from 1 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg
Placebo komparator: Placebo,single ascending dose (Part A)
Matched placebo administered as single ascending doses in parallel to AC-084
Placebo capsules matching AC-084 capsules
Eksperimentell: AC-084, multiple ascending dose (Part B)
AC-084 administered in a twice daily (b.i.d.) dosing regimen at multiple dose levels. The starting dose will be between 1 and 30 mg and will be selected on the basis of the safety and pharmacokinetic results of the part A. Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg
Placebo komparator: Placebo,multiple ascending dose (Part B)
Matched placebo administered as multiple ascending doses in parallel to AC-084
Placebo capsules matching AC-084 capsules
Eksperimentell: AC-084, single dose (Part C)
Up to 6 subjects in part C will receive AC-084 administered at a single dose (foreseen to be 100 mg)
Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of participants with adverse events (AEs) (Part A)
Tidsramme: From dosing until day 4
Treatment-emergent AEs and treatment-emergent serious AEs
From dosing until day 4
Number of participants with adverse events (AEs) (Part B)
Tidsramme: From dosing until day 8
Treatment-emergent AEs and treatment-emergent serious AEs
From dosing until day 8
Number of participants with adverse events (AEs) (Part C)
Tidsramme: From dosing until day 6
Treatment-emergent AEs and treatment-emergent serious AEs
From dosing until day 6
Incidence of safety events of interest (Part A)
Tidsramme: From dosing until day 4
Events of interest are any abnormalities in ECG, vital signs or laboratory test results
From dosing until day 4
Incidence of safety events of interest (Part B)
Tidsramme: From dosing until day 8
Events of interest are any abnormalities in ECG, vital signs or laboratory test results
From dosing until day 8
Incidence of safety events of interest (Part C)
Tidsramme: From dosing until day 6
Events of interest are any abnormalities in ECG, vital signs or laboratory test results
From dosing until day 6

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Maximum plasma concentration (Cmax) following single oral ascending doses (Part A)
Tidsramme: From dosing until day 4
Cmax is derived from the observed plasma concentration-time curves
From dosing until day 4
Maximum plasma concentration (Cmax) following single oral ascending doses (Part B)
Tidsramme: From dosing until day 8
Cmax is derived from the observed plasma concentration-time curves
From dosing until day 8
Maximum plasma concentration (Cmax) following single oral ascending doses (Part C)
Tidsramme: From dosing until day 6
Cmax is derived from the observed plasma concentration-time curves
From dosing until day 6
Time to reach Cmax (tmax) following single oral ascending doses (Part A)
Tidsramme: From dosing until day 4
Tmax is derived from the observed plasma concentration-time curves
From dosing until day 4
Time to reach Cmax (tmax) following single oral ascending doses (Part B)
Tidsramme: From dosing until day 8
Tmax is derived from the observed plasma concentration-time curves
From dosing until day 8
Time to reach Cmax (tmax) following single oral ascending doses (Part C)
Tidsramme: From dosing until day 6
Tmax is derived from the observed plasma concentration-time curves
From dosing until day 6
Terminal half-life [t(1/2)] following single oral ascending doses (Part A)
Tidsramme: From dosing until day 4
From dosing until day 4
Terminal half-life [t(1/2)] following single oral ascending doses (Part B)
Tidsramme: From dosing until day 8
From dosing until day 8
Terminal half-life [t(1/2)] following single oral ascending doses (Part C)
Tidsramme: From dosing until day 6
From dosing until day 6
Area under the plasma concentration-time curve (AUC) following single oral ascending doses (Part A)
Tidsramme: From dosing until day 4
AUC is defined for the time intervals from zero to time t of the last measured concentration above the limit of quantification and from zero to infinity
From dosing until day 4
Area under the plasma concentration-time curve (AUC) following single oral ascending doses (Part B)
Tidsramme: From dosing until day 8
AUC is defined for the time intervals from zero to time t of the last measured concentration above the limit of quantification and from zero to infinity
From dosing until day 8
Area under the plasma concentration-time curve (AUC) following single oral ascending doses (Part C)
Tidsramme: From dosing until day 6
AUC is defined for the time intervals from zero to time t of the last measured concentration above the limit of quantification and from zero to infinity
From dosing until day 6

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Martine Géhin, PhD, Actelion

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

12. september 2016

Primær fullføring (Faktiske)

10. desember 2017

Studiet fullført (Faktiske)

10. desember 2017

Datoer for studieregistrering

Først innsendt

31. august 2016

Først innsendt som oppfylte QC-kriteriene

14. september 2016

Først lagt ut (Anslag)

19. september 2016

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. juli 2018

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. juli 2018

Sist bekreftet

1. juli 2018

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • AC-084-101

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere